CHYM investors were likely "fudded out" by the IPO lockup expiration, not the Q3 beat and raise. The author doubled their position, anticipating that funds won't sell at an 80% loss given the 2021 Series G valuation of CHYM at $25B. This suggests a potential undervaluation and opportunity for a rebound.